Jaguar Health, Inc. (JAGX)
| Market Cap | 3.38M |
| Revenue (ttm) | 11.51M |
| Net Income (ttm) | -53.58M |
| Shares Out | 14.04M |
| EPS (ttm) | -22.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 694,424 |
| Open | 0.290 |
| Previous Close | 0.280 |
| Day's Range | 0.240 - 0.294 |
| 52-Week Range | 0.240 - 13.250 |
| Beta | 0.29 |
| Analysts | Strong Buy |
| Price Target | 60.00 (+24,796.27%) |
| Earnings Date | Apr 7, 2026 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiret... [Read more]
Financial Performance
In 2025, Jaguar Health's revenue was $11.51 million, a decrease of -1.52% compared to the previous year's $11.69 million. Losses were -$53.58 million, 39.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for JAGX stock is "Strong Buy" and the 12-month stock price target is $60.0.
News
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire...
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug design...
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders...
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0 Billion by 20331 AI data mining of real world clinical and symptom manifestation is beneficial in the...
Jaguar Health Earnings Call Transcript: Q4 2025
Q4 2025 net revenue rose 5% sequentially but fell 8% year-over-year, with a strategic shift to rare disease focus and a transformative out-license deal securing $16M upfront. Clinical milestones for crofelemer in intestinal failure are expected in the next 6-12 months.
Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) Participation Instructions for Webcast When: Friday, April 10, 2026 at 8:30 a.m. Eastern ...
Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyr...
Jaguar Health Reports 2025 Financials
Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® an...
Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID)...
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction coul...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("...
Jaguar Health Transcript: Life Sciences Virtual Investor Forum
Secured major non-dilutive funding through a licensing deal, fueling late-stage clinical programs for rare diseases MVID and SBS-IF. Proof of concept data show significant reductions in parenteral support, with pivotal trials and regulatory filings underway.
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, ...
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure in...
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
As announced , Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two co...
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / March 2, 2026 / Jaguar Health, Inc...
Jaguar Health Announces a Special One-time Stock Dividend
Dividend intended to provide dilution protection to Jaguar shareholders as company explores pathway to restructure debt SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2026 / Jaguar Health, Inc. (N...
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an addi...
Jaguar Health Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
A major licensing deal with FuturePak provides significant non-dilutive funding and shifts commercial focus to R&D and rare disease programs. Clinical trials for MVID and SBS show promising results, supporting accelerated regulatory pathways and potential blockbuster opportunities.
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts
SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday...
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million
$18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions) Up to additional $20M in milestone and other future payments Future Pak becomes exclusive U.S...
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication
Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure Associate...
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center...
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in Octobe...
Jaguar Health Transcript: Emerging Growth Conference 88
FDA renewed conditional approval for Canalevia-CA1 in dogs, with a $250,000 grant supporting pivotal trials for full approval. Expansion into Europe and broader indications is underway, with significant market potential and key catalysts expected through 2025.